IP Library Granted Patent US 10,398,711
Granted Patent B2
US 10,398,711 · App. 15/861,241 · Granted Sep 3, 2019

C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Inventors: Xin Jiang (Coppell, TX); Christopher F. Bender (Garland, TX); Melean Visnick (Irving, TX)
Assignee: REATA PHARMACEUTICALS, INC.
A61K31/58C07D271/06C07D271/10C07J63/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,398,711
App. No.
15/861,241
Granted
Sep 3, 2019
Kind
B2
Abstract

Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.

Claims (27)

1. A compound of the formula:

wherein:

n is 0 or 1;

Ar is

 and

Y is:

hydrogen, alkyl (C≤8) , or substituted alkyl (C≤8) ;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , further defined as:

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising:

a) the compound of claim 1 ; and

b) an excipient.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 053034/0018 →
SECURITY INTEREST Recorded Jun 14, 2018
From: REATA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 046357/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2018
From: JIANG, XIN; BENDER, CHRISTOPHER F.; VISNICK, MELEAN
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 044525/0904 →
Continuity (5)
Division 15349086 · Nov 11, 2016
Division 14566827 · Dec 11, 2014
Continuation In Part 14022843 · Sep 10, 2013
Provisional Application 61699199 · Sep 10, 2012
Related Publication 20180235981A1 · Aug 23, 2018
Cited By (4)
US 12,344,631 US 12,358,866 US 12,384,815 US 12,545,701